Tonix Pharmaceuticals today
Tonix Pharmaceuticals
- 52-week range
- $ 0.12
▼
$ 12.48
- Value is valuable
- $ 53.50
The Biopharmaceutical Company of the Clinical Stage Tonix Pharmaceuticals NASDAQ: TNXP He receives considerable attention from investors and market participants. The company develops therapy for conditions with high unsatisfied needs, with an emphasis on pain management, central nervous system disorders and vaccines against public health. The leading product Tonix, TNX-102 SL (Tonmya ™) is a potential treatment for fibromyalgia, a chronic painkiller in affecting millions. The company’s main attention on this and other conditions with high unsatisfied needs in combination with its pipeline of drug candidates made it a biopharmaceutical company.
Fibromyalgia: Widespread problem
Fibromyalgia is a chronic disease affecting millions of adults, and women make up most victims. Characterizing a constant, widespread musculoskeletal pain, this condition often brings with it many other exhausting symptoms, including spawning sleep, severe fatigue and cognitive dysfunction, often described as “fog of the brain”.
TNX-102 SL: aiming for the main reason
TNX-102 SL (Tonmya ™) представляет собой таблетку Subingual Cyclobenzaprine HCL, которая является неооооооооооооооооооооооооооооооооооооооооооооооооооооо подаватостью для пациентов с фибромиалгией. Its unique mechanism of action -targets violated the dream, interacting with multiple neuroreceptors in the brain. Sublingval administration provides rapid absorption and costs the metabolism of the liver of the first passage, potentially increasing its safety and effectiveness. Phase 3 tests showed a significant decrease in pain and improving the quality of sleep, fatigue and general symptoms of fibromyalgia. The drug was well tolerated, with a slight, transitional language or numbness of the mouth as the most common side effect.
Regulatory and commercialization roadmap
The adoption of the FDA on the NDA for TNX-102 SL in December 2024 marked a critical step towards potential approval. The assigned law on the fee for the use of drugs by prescription (PDUFA) on August 15, 2025 creates a clear time for monitoring investors. FDA has already provided a quick designation of TNX-102 SL in July 2024, which emphasizes the unsatisfied medical need for fibromalgia.
Anticipating the potential statement and launch of 2025, Tonix strengthened its commercial team of leadership with strategic employees. Gary Einsworth brings more than two decades of experience in access to the market, Bradley Raudabo has a strong track record in the field of marketing and launching products in the space of the central nervous system, and Errol Guld adds more than 25 years of experience in medical affairs, with previous consulting experience with Tonix. These additions, along with market research, indicating potential introduction by doctors and the creation of educational resources, demonstrate the company’s commitment to successful launch.
Market opportunities and competitive landscape
Since more than 10 million adults in the United States affected by fibromyalgia, a market opportunity for new treatment is significant. It is expected that the current market for the treatment of fibromalgia will reach 4.13 billion dollars. USA worldwide by 2032. The lack of effective treatment options combined with significant dissatisfaction of the patient with current therapy, some of which have been available for more than 15 years, ensures the potential administration of a new drug as TNX-102 SL even more convincing.
The existing FDA-approved methods of treatment, although available, do not completely solve the complex needs of patients with fibromyalgia, and, therefore, there is a high unsatisfied need for this group of patients. This lack of effectiveness is even more aggravated by the widespread use of opioids as the last means for treating fibromalgia pain. Some studies even showed that some patients with fibromyalgia are more likely to prescribe opioids who carry the risks of dependence and dependence, and not the currently approved treatment.
Diversified portfolio tonic
Tonics cultivated a wide pipeline in several therapeutic areas. The company’s immunology portfolio has TNX-1500, monoclonal antibodies aimed at rejection of organs transplantation, autoimmune disorders and cancer. In infectious diseases, the company develops TNX-801, a living viral vaccine aimed at MPOX and OSPU, and TNX-1800, candidate for the Covid-19 vaccine. These programs use the established Tonix capabilities in the development and production of a vaccine against the virus at its enterprise in Montana.
Additional programs include TNX-1300 for cocaine and TNX-1900 intoxication for migraine prevention, among other things. The TNX-4200 program, financed under the contract of threat reduction (DTRA), and AI cooperation with X-CheM, which highlights the Tonix focus on antivirus drugs of a wide range of host meters with a wide range of viruses, including TNX-3500 and TNX-102. In addition, two market migraines, two migraines, Zembrace and Tosymra, provide another income stream.
Financial health and market dynamics: bull forecast?
Tonix Pharmaceuticals is forecasted today
$ 53.50
13 978.95% growthBuy
Based on 2 analysts ratings
| High forecast | $ 96.00 |
|---|---|
| Average forecast | $ 53.50 |
| Low forecast | $ 11.00 |
Tonix Pharmaceuticals predicts details
As of January 30, 2025, Tonix Pharmaceuticals shares are traded about $ 0.40, which increases an increase of 160% over the past three months. While the recent Tonix market capitalization is about $ 75 million, the 52-week of shares provides an image of its volatility, fluctuating from a minimum of $ 0.12 and a maximum of $ 12.48. The current price of shares, much lower than its 52-week maximum, can provide the opportunity for investors who believe in the long-term prospects of the company. These fluctuations reflect the inherent volatility, often observed in the biotechnological sector, especially for such clinical stages as Tonix.
Tonix Pharmaceuticals income for the third quarter of 2024 (3 quarters of 2024) revealed a clean loss of 14.2 million dollars. USA or $ 0.23 per share, which has improved significantly on consensus assessment of $ 1.80. While the company’s net loss for nine months that ended on September 30 was more than in the previous period of $ 107.9 million. USA, this includes $ 58.95 million. USA in the form of non -compliance with non -compliance. The revenue for nine months has grown significantly compared to last year, $ 7.51 million. Although this income comes from sales of their existing, approved medicines for migraine, it provides a source of indistinguishable financing, while investors expect the approval of the TNX-102 SL.
Diversified approach to unsatisfied needs
Tonix Pharmaceuticals is in the turning point in its history. The adoption of FDA NDA for TNX-102 SL and the upcoming date PDUFA means a promising opportunity. A strong Tonix pipeline, reliable clinical data and a significant unsatisfied need for the effective treatment of fibromyalgia, everyone indicates its potential for market violations. Although the current price of shares shows some volatility that is typical of the biotechnological sector, the positive development path of the TNX-102 SL, a fortified commercial team and a diversified portfolio involves the potential for future growth. Despite current financial losses, Tonix strategically commercials existing products to support future financing and display the TNX-102 SL to the market. The concentration of the company’s attention on the development of new, effective and safe treatment methods for a wide range of conditions positions it competitively for long -term success.
Before considering Tonix Pharmaceuticals, you will want to hear it.
Marketbeat monitors the highest and most effective analysts with the most effective Wall Street analysts and promotions that they recommend to their customers daily. Marketbeat has identified five shares that leading analysts quietly whisper to their clients to buy now before the wider market was stuck … and Tonix Pharmaceuticals was not on the list.
While Tonix Pharmaceuticals currently has a “purchase” rating among analysts, analysts with the highest rating believe that these five promotions are better buying.
View five shares here
Marketbeat has just published its list of 10 cheap shares that have been missed by the market and can be seriously underestimated. Enter your email address and below to see which companies have compiled a list.
Get this free report